Details of the Drug

General Information of Drug (ID: DMSLJZ8)

Drug Name

BI 706321

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Phase 2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

References

1	ClinicalTrials.gov (NCT04978493) A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients With Crohn's Disease (CD) Receiving Ustekinumab Induction Treatment. U.S.National Institutes of Health.